Back To Search Results

Telogen Effluvium

Editor: Dahlia Saleh Updated: 5/1/2024 11:24:56 PM

Introduction

Telogen effluvium is a form of nonscarring alopecia characterized by diffuse, often acute, hair shedding.[1][2][3][4][5] Another form that is chronic with a more insidious onset also exists. Telogen effluvium is the excessive shedding of resting or telogen hair after some metabolic stress, hormonal changes, or medication. Telogen hair is also known as club hair due to the shape of the root. In a normal, healthy individual's scalp, about 85% is anagen hair, and 15% is telogen hair. Anagen hair is actively growing hair, whereas telogen hair is resting hair. A few hairs may also be in the catagen or transition phase. A hair follicle typically produces anagen hair for almost 4 years and then rests for about 4 months. A new anagen hair grows under the resting telogen hair and pushes it out. If the body remains under significant stress, approximately 70% of anagen hair precipitates into the telogen phase, thus causing hair loss.[6]

Telogen effluvium is a reactive process triggered by metabolic stress, hormonal changes, or medications. Common triggering events include acute febrile illness, severe infection, major surgery, severe trauma, postpartum hormonal changes (particularly a decrease in estrogen), hypothyroidism, discontinuing estrogen-containing medication, crash dieting, low protein intake, heavy metal ingestion, and iron deficiency. Many medications have been linked to telogen effluvium, but the most common are beta-blockers and retinoids, including excess vitamin A, anticoagulants, propylthiouracil, carbamazepine, and immunizations. 

Etiology

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Etiology

Telogen effluvium is a reactive process triggered by metabolic stress, hormonal changes, or medications. Common triggering events include acute febrile illness; severe infection;[7] major surgery; severe trauma; postpartum hormonal changes, particularly a decrease in estrogen; hypothyroidism;[8] sudden discontinuation of estrogen-containing medications; crash dieting; low protein intake; heavy metal ingestion; and iron deficiency. Many medications have been linked to telogen effluvium, but the most common are beta-blockers; retinoids, including excess vitamin A; anticoagulants; propylthiouracil; carbamazepine; and immunizations.[9]

Epidemiology

Telogen effluvium is a condition that can affect individuals of any age, gender, or racial background. The exact prevalence of telogen effluvium is unknown, but it is considered quite common. Many adults experience an episode of telogen effluvium at some point in their lifetime.[10] Although telogen effluvium can manifest in both men and women, women tend to be more susceptible because of postpartum hormonal changes. In addition, women are more disturbed by hair shedding compared to men and are more likely to seek medical attention.[11][12][13][14]

Pathophysiology

Telogen effluvium is triggered when physiologic stress causes a large number of hairs in the growing phase (anagen phase) of the hair cycle to abruptly enter the resting phase (telogen phase). During this phase, the growth of the telogen hairs ceases for 1 to 6 months (on average 3 months), though the patient does not notice this cessation of growth. When the affected hairs re-enter the growth phase (anagen phase), the hair strands that had been suspended in the resting phase (telogen) are extruded from the follicle, resulting in noticeable hair shedding.

At a molecular level, etiological factors may disturb the intricate balance of growth factors, neuroendocrine signals, and cytokine involvement in follicular homeostasis. This disturbance can lead to premature catagen induction or prolongation, accelerating the transition of hairs into the telogen phase.

Pertinent research in recent years suggests the involvement of inflammatory mediators, oxidative stress, and changes in the microenvironment of the hair follicle niche in perpetuating telogen effluvium. The involvement of multiple pathways indicates the complexity of telogen effluvium's pathophysiology and provides potential targets for efficient diagnosis and therapeutic intervention.[15]

Histopathology

Histological findings in telogen effluvium are best observed with transverse sections of a punch biopsy. The number and density of hair follicles are typically normal, but there is an increased percentage of hair follicles in the catagen or the telogen phase.[15] If at least 25% but not more than 50% of the follicles are in the telogen phase, the diagnosis of telogen effluvium is confirmed.

History and Physical

Patients typically present with hair shedding, usually without other symptoms and with a relatively abrupt onset. By definition, the shedding in acute telogen effluvium lasts less than 6 months; often, the shedding period is much shorter. Obtaining a thorough history can reveal a causative event (refer to the list in the Etiology section for the conditions that may be considered) occurring approximately 3 months before the onset of the shedding. However, this timeframe could range from 1 to 6 months. Frequently, the patient may have completely recovered from the acute illness or identifiable incident and may not recognize the connection with the hair loss.[16]

The physical examination is grossly normal, as it is difficult for the casual observer to appreciate the volume of hair loss. Comparing the patient's current appearance with old pictures can be beneficial (see Image. Telogen Effluvium in a Patient After Prolonged Crash Diet). If the patient presents during the acute shedding, a gentle pull test results in the removal of at least four hairs with each pull. However, if the patient presents after the acute shedding has passed, the pull test may yield normal results. A thorough examination of the scalp may reveal an increased percentage of short anagen hairs growing close to the scalp, and no scarring should be evident.

Evaluation

Typically, obtaining a detailed history and performing a thorough physical examination are sufficient for diagnosing telogen effluvium. If a biopsy is performed during the acute shedding phase (when the pull test is positive), it can confirm an increase in the percentage of telogen hairs.[15] Testing for underlying hormonal conditions, such as hypothyroidism; chronic metabolic illnesses; or iron deficiency is recommended if there are concerns about these conditions.[17][18]

Laboratory Testing

Hypothyroidism

  • Hypothyroidism can lead to chronic telogen effluvium.
  • When symptoms of hypothyroidism, such as tiredness, constipation, weight gain, and cold sensitivity, are present, a thyrotropin test is warranted.[19]

Iron deficiency

  • Iron deficiency should be evaluated with a complete blood count, serum iron, iron saturation, and ferritin. [20]
  • Given the priority of blood for survival over hair, the body prioritizes shedding hair before red blood cell indices become microcytic.
  • Ferritin acts as an acute-phase reactant, and inflammation can result in normal ferritin levels in an iron-deficient individual.
  • Low ferritin confirms iron deficiency; a normal ferritin level does not exclude iron deficiency.
  • Iron saturation is the most sensitive indicator of iron deficiency. 

Syphilis

  • When symptoms of syphilis, such as fatigue, patchy hair loss, sore throat, or swollen lymph nodes, are present and considered a cause, a rapid plasma reagin or venereal disease research laboratory (VDRL) test should be performed.

Biopsy

  • Scalp biopsy is the most useful test to confirm the diagnosis, but it is seldom necessary if gentle hair pull produces numerous telogen hairs.
  • A white bulb and no gelatinous hair sheath can identify telogen hair.
  • If a patient is unwilling to allow a scalp biopsy, serial hair collections can be obtained.
  • The patient should be instructed to collect all shedding hair in 24 hours, refraining from washing their hair during this time. This process should be repeated every week for three or four collections.
  • Collecting 100 or more hairs in 24 hours suggests telogen effluvium. The number of hairs collected may decrease if the collections are performed over several weeks while the telogen effluvium improves. 

Treatment / Management

Acute telogen effluvium is a self-limited condition. If the causative event has been identified and appropriately treated, there is no need for further treatment. If a hormonal or dietary imbalance, such as low iron levels, zinc levels, vitamin D levels; or metabolic illness is present, hair growth returns after these factors are corrected.[21] If a medication is the cause of the shedding, hair growth restarts after the medication is withdrawn.[22](B3)

Although topical minoxidil has not been proven to promote hair recovery in telogen effluvium, it has theoretical benefits. Patients who wish to take an active role in their treatment may choose to use topical minoxidil. Recent trials have proven that oral minoxidil can be an effective and well-tolerated treatment alternative for healthy patients with difficulty with topical formulations.[23]

Recent studies have also shown that both botulinum toxin A and multivitamin mesotherapy are effective in treating telogen effluvium. These treatments demonstrated improvement of the criteria terminal hair and multiple follicular units.[24] (B2)

Most importantly, all the patients should be offered emotional support and reassurance about the benign course of the disease and the possibility of complete recovery of hair with time and nutritional support. 

Differential Diagnosis

The differential diagnoses of telogen effluvium include alopecia areata, anagen effluvium, androgenetic alopecia, scarring alopecia, syphilis, and trichotillomania.

Prognosis

Morbidity associated with telogen effluvium is typically limited to mild cosmetic changes, and there have been no reports of mortality.

  • Telogen effluvium has a significant psychological impact on individuals affected by the disease, and therefore, counseling is required. 
  • The prognosis for a good recovery of hair density occurs in acute telogen effluvium.
  • A good cosmetic outcome is also expected in chronic telogen effluvium, even if the hair shedding continues.

Complications

Telogen effluvium is a benign and spontaneously reversible condition with no associated complications. As it is a non-cicatricial alopecia, the scalp has no scarring, even during the active hair loss phase.

Deterrence and Patient Education

Hair growth may take up to 6 months to restart and even longer for the growth to be appreciated by the patient. Patients often require the reassurance of the normal recovery of their hair while the hair re-enters the anagen phase and grows normally. Patients may also worry that normal grooming of their hair worsens hair shedding. Patients should be reassured that their hair is normal and they can continue to wash and style it as usual.

Enhancing Healthcare Team Outcomes

The diagnosis and management of hair loss involve an interprofessional team comprising a dermatologist, primary care provider, nurse practitioner, and internist. Telogen effluvium is a type of nonscarring alopecia characterized by diffuse and often acute hair shedding. In most cases, no specific cause is identified. In any case, patients should be informed that the condition is self-limiting. Prescribing hair growth medications or referring patients for hair transplants is unnecessary. Although hair growth may take several months to a year to fully restore, the outcome is generally favorable for most patients.[25][26]

Media


(Click Image to Enlarge)
<p>Telogen Effluvium in a Patient After Prolonged Crash Diet

Telogen Effluvium in a Patient After Prolonged Crash Diet. The image shows the patient's scalp with hair loss resulting from prolonged crash dieting.

Contributed by Hasnain Ali Syed, MD

References


[1]

Nistico S, Tamburi F, Bennardo L, Dastoli S, Schipani G, Caro G, Fortuna MC, Rossi A. Treatment of telogen effluvium using a dietary supplement containing Boswellia serrata, Curcuma longa, and Vitis vinifera: Results of an observational study. Dermatologic therapy. 2019 May:32(3):e12842. doi: 10.1111/dth.12842. Epub 2019 Feb 8     [PubMed PMID: 30693615]

Level 2 (mid-level) evidence

[2]

Sari Aslani F, Heidari Esfahani M, Sepaskhah M. Non-scarring Alopecias in Iranian Patients: A Histopathological Study With Hair Counts. Iranian journal of pathology. 2018 Summer:13(3):317-324     [PubMed PMID: 30636954]


[3]

Sahin G, Pancar GS, Kalkan G. New pattern hair loss in young Turkish women; What's wrong in their daily life? Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI). 2019 May:25(3):367-374. doi: 10.1111/srt.12662. Epub 2019 Jan 5     [PubMed PMID: 30614076]


[4]

Stoehr JR, Choi JN, Colavincenzo M, Vanderweil S. Off-Label Use of Topical Minoxidil in Alopecia: A Review. American journal of clinical dermatology. 2019 Apr:20(2):237-250. doi: 10.1007/s40257-018-0409-y. Epub     [PubMed PMID: 30604379]


[5]

Daly T, Daly K. Telogen Effluvium With Dysesthesia (TED) Has Lower B12 Levels and May Respond to B12 Supplementation. Journal of drugs in dermatology : JDD. 2018 Nov 1:17(11):1236-1240     [PubMed PMID: 30500148]


[6]

Asghar F, Shamim N, Farooque U, Sheikh H, Aqeel R. Telogen Effluvium: A Review of the Literature. Cureus. 2020 May 27:12(5):e8320. doi: 10.7759/cureus.8320. Epub 2020 May 27     [PubMed PMID: 32607303]


[7]

Tešanović Perković D, Vukojević M, Bukvić Mokos Z. Post-COVID Telogen Effluvium. Acta dermatovenerologica Croatica : ADC. 2022 Dec:30(4):220-226     [PubMed PMID: 36919388]


[8]

Bin Dayel S, Hussein RS, Atia T, Abahussein O, Al Yahya RS, Elsayed SH. Is thyroid dysfunction a common cause of telogen effluvium?: A retrospective study. Medicine. 2024 Jan 5:103(1):e36803. doi: 10.1097/MD.0000000000036803. Epub     [PubMed PMID: 38181279]

Level 2 (mid-level) evidence

[9]

Zhang D, LaSenna C, Shields BE. Culprits of Medication-Induced Telogen Effluvium, Part 1. Cutis. 2023 Dec:112(6):267-271. doi: 10.12788/cutis.0910. Epub     [PubMed PMID: 38290075]


[10]

Seyfi S, Alijanpour R, Aryanian Z, Ezoji K, Mahmoudi M. Prevalence of telogen effluvium hair loss in COVID-19 patients and its relationship with disease severity. Journal of medicine and life. 2022 May:15(5):631-634. doi: 10.25122/jml-2021-0380. Epub     [PubMed PMID: 35815081]


[11]

Sant'Anna Addor FA, Donato LC, Melo CSA. Comparative evaluation between two nutritional supplements in the improvement of telogen effluvium. Clinical, cosmetic and investigational dermatology. 2018:11():431-436. doi: 10.2147/CCID.S173082. Epub 2018 Sep 10     [PubMed PMID: 30237729]

Level 2 (mid-level) evidence

[12]

Udompanich S, Chanprapaph K, Suchonwanit P. Hair and Scalp Changes in Cutaneous and Systemic Lupus Erythematosus. American journal of clinical dermatology. 2018 Oct:19(5):679-694. doi: 10.1007/s40257-018-0363-8. Epub     [PubMed PMID: 29948959]


[13]

Saleh D, Nassereddin A, Cook C. Anagen Effluvium. StatPearls. 2024 Jan:():     [PubMed PMID: 29493918]


[14]

Motosko CC, Bieber AK, Pomeranz MK, Stein JA, Martires KJ. Physiologic changes of pregnancy: A review of the literature. International journal of women's dermatology. 2017 Dec:3(4):219-224. doi: 10.1016/j.ijwd.2017.09.003. Epub 2017 Oct 21     [PubMed PMID: 29234716]


[15]

Yorulmaz A, Hayran Y, Ozdemir AK, Sen O, Genc I, Gur Aksoy G, Yalcin B. Telogen effluvium in daily practice: Patient characteristics, laboratory parameters, and treatment modalities of 3028 patients with telogen effluvium. Journal of cosmetic dermatology. 2022 Jun:21(6):2610-2617. doi: 10.1111/jocd.14413. Epub 2021 Aug 27     [PubMed PMID: 34449961]


[16]

Jimeno Ortega I, Stefanato CM. Telogen effluvium: a 360 degree review. Italian journal of dermatology and venereology. 2023 Dec:158(6):457-466. doi: 10.23736/S2784-8671.23.07579-5. Epub     [PubMed PMID: 38015483]


[17]

Mirallas O, Grimalt R. The Postpartum Telogen Effluvium Fallacy. Skin appendage disorders. 2016 May:1(4):198-201. doi: 10.1159/000445385. Epub 2016 Apr 20     [PubMed PMID: 27386466]


[18]

Malkud S. Telogen Effluvium: A Review. Journal of clinical and diagnostic research : JCDR. 2015 Sep:9(9):WE01-3. doi: 10.7860/JCDR/2015/15219.6492. Epub 2015 Sep 1     [PubMed PMID: 26500992]


[19]

Kakpovbia E, Ogbechie-Godec OA, Shapiro J, Lo Sicco KI. Laboratory Testing in Telogen Effluvium. Journal of drugs in dermatology : JDD. 2021 Jan 1:20(1):110-111. doi: 10.36849/JDD.5771. Epub     [PubMed PMID: 33400415]


[20]

İbiş S, Aksoy Saraç G, Akdağ T. Evaluation of MCV/RDW Ratio and Correlations With Ferritin in Telogen Effluvium Patients. Dermatology practical & conceptual. 2022 Jul:12(3):e2022151. doi: 10.5826/dpc.1203a151. Epub 2022 Jul 1     [PubMed PMID: 36159144]


[21]

Saini K, Mysore V. Role of vitamin D in hair loss: A short review. Journal of cosmetic dermatology. 2021 Nov:20(11):3407-3414. doi: 10.1111/jocd.14421. Epub 2021 Sep 22     [PubMed PMID: 34553483]


[22]

Mysore V, Parthasaradhi A, Kharkar RD, Ghoshal AK, Ganjoo A, Ravichandran G, Saraswat A, Shah Y, Singh M, Remadevi TJ, Matte P. Expert consensus on the management of Telogen Effluvium in India. International journal of trichology. 2019 May-Jun:11(3):107-112. doi: 10.4103/ijt.ijt_23_19. Epub     [PubMed PMID: 31360038]

Level 3 (low-level) evidence

[23]

Randolph M, Tosti A. Oral minoxidil treatment for hair loss: A review of efficacy and safety. Journal of the American Academy of Dermatology. 2021 Mar:84(3):737-746. doi: 10.1016/j.jaad.2020.06.1009. Epub 2020 Jul 2     [PubMed PMID: 32622136]


[24]

Khattab FM, Rady A, Khashaba SA. Recent modalities in treatment of telogen effluvium: Comparative study. Dermatologic therapy. 2022 Oct:35(10):e15720. doi: 10.1111/dth.15720. Epub 2022 Aug 8     [PubMed PMID: 35851518]

Level 2 (mid-level) evidence

[25]

Mubki T, Rudnicka L, Olszewska M, Shapiro J. Evaluation and diagnosis of the hair loss patient: part I. History and clinical examination. Journal of the American Academy of Dermatology. 2014 Sep:71(3):415.e1-415.e15. doi: 10.1016/j.jaad.2014.04.070. Epub     [PubMed PMID: 25128118]


[26]

Hamm H. [Acquired alopecia in childhood]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 2013 May:64(5):371-9; quiz 380-1. doi: 10.1007/s00105-013-2554-9. Epub     [PubMed PMID: 23571647]